CEO, WntRx Pharmaceuticals
Targeting the BCL9/Beta-Catenin Complex with Stapled Peptides
WntRx Pharmaceuticals is a preclinical-stage biopharmaceutical company focused on developing cancer therapies targeting the Wnt signaling pathway. The Wnt pathway has long been implicated as an important avenue to impact cancer biology, however successful development of small molecule or antibody inhibitors has been hampered by safety issues and suboptimal efficacy. WntRx is addressing these challenges by optimizing potent and selective peptide inhibitors of the BCL-9/beta-catenin complex, a downstream protein-protein interaction in the Wnt signaling pathway that drives transcription of oncogenes and inhibits anti-cancer immune response.